The authors conducted a retrospective study of failure rates and performed a cost-minimization analysis of azithromycin and clarithromycin.
You are here
P&T® Journal contents for October 2003
Dr. Babinchak talks about the unexpected turns during his career in the field of infectious diseases.
Principles of Antibiotic Formulary Selection for P&T Committees, Part 5: The Cost of Antimicrobial Therapy
Dr. Cunha describes some of the cost factors that P&T committees should consider when selecting antibiotics.
Dr. Micozzi provides an overview of the changes taking place in traditional medicine and the new roles of “alternative,” “complementary,” and “holistic” healing practices.
Dr. Goldenberg reviews bortezomib for injection (Velcade™) for multiple myeloma, gefitinib (Iressa™) for non-small cell lung cancer, and Bexxar® for non-Hodgkin’s lymphoma.